In silicomapping of allosteric ligand binding sites in type‐1 cannabinoid receptor
- 3 January 2018
- journal article
- research article
- Published by Wiley in Biotechnology and Applied Biochemistry
- Vol. 65 (1) , 21-28
Abstract
The recent resolution of the crystal structure of type‐1 cannabinoid receptor (CB1) and the discovery of novel modulators for this target open the way to the possibility of elucidating the structural requirements for CB1binding, and thereby facilitate a rational drug design. Compounds that target the orthosteric site of CB1in some cases have shown side effects. Allosteric modulators could potentially avoid these side effects by influencing binding and/or efficacy of orthosteric ligands. Here, we summarize and compare previous data on different putative allosteric binding sites observed in CB1homology models with anin silicodocking study of the recently published crystal structure of the same receptor on endogenous and natural hydrophobic ligands that act as positive allosteric modulators and negative allosteric modulators of CB1. In particular, a lipid‐exposed pocket targeted by most of the tested molecules is reported and discussed.Keywords
This publication has 35 references indexed in Scilit:
- Anti-inflammatory lipoxin A4is an endogenous allosteric enhancer of CB1cannabinoid receptorProceedings of the National Academy of Sciences, 2012
- Effects of palmitoylation of Cys415in helix 8 of the CB1cannabinoid receptor on membrane localization and signallingBritish Journal of Pharmacology, 2011
- SwissDock, a protein-small molecule docking web service based on EADock DSSNucleic Acids Research, 2011
- Fast docking using the CHARMM force field with EADock DSSJournal of Computational Chemistry, 2011
- CHARMM: The biomolecular simulation programJournal of Computational Chemistry, 2009
- Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disordersNature Reviews Drug Discovery, 2009
- Beta-caryophyllene is a dietary cannabinoidProceedings of the National Academy of Sciences, 2008
- Antiobesity Efficacy of a Novel Cannabinoid-1 Receptor Inverse Agonist, N-[(1 S,2 S)-3-(4-Chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), in RodentsThe Journal of Pharmacology and Experimental Therapeutics, 2007
- UCSF Chimera—A visualization system for exploratory research and analysisJournal of Computational Chemistry, 2004
- SR141716A, a potent and selective antagonist of the brain cannabinoid receptorFEBS Letters, 1994